San Diego Life Sciences Roundup: Accelrys, Celladon’s IPO, and More
A buyout offer for Accelrys, a new stem cell center of excellence, and an IPO. Not bad for one week of life sciences news. But wait, there’s more…
—French software developer Dassault Systèmes agreed to pay $750 million in cash to buy San Diego’s Accelrys (NASDAQ: ACCL), a smaller American rival that specializes in scientific and product lifecycle management software. The board at Accelrys has approved the deal, which extends Dassault Systèmes’ lineup in product lifecycle management software, 3D modeling, and basic scientific research and discovery. The French giant also gets about 2,000 Accelrys customers, including Sanofi, Pfizer, GSK, AstraZeneca, Du Pont, Shell, BASF, P&G, Unilever, and L’Oréal.
—Shares of San Diego-based Celladon (NASDAQ: CLDN) opened well above its $8-per-share IPO price yesterday, but slid from a midday high of $9.90 to close at $8.18 as more than 1.7 million shares changed hands on its first day of regular trading. Celladon, which is developing a gene therapy for patients with systolic heart failure, raised about $44 million in its IPO, which was postponed as the market for biotech IPOs stalled a bit in November. The pre-revenue company has raised about $120 million from venture investors Enterprise Partners Venture Capital, Pfizer Ventures, Lundbeckfond Ventures, Novartis Venture Funds, Johnson & Johnson Development, GBS Venture partners, Venrock, and H&Q Healthcare.